

Hybrigenics 2011 full year results

Losses cut by half due to an exceptional increase in revenue and improved cash position

Sustained investments in intellectual property and new therapeutic indications for inecalcitol

Hybrigenics Services: growing revenues and profit margin

Paris, 16 April 2012 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases announces today its consolidated results for the full year ended December 31st, 2011 and the results of Hybrigenics Services SAS, its fully-owned subsidiary dedicated to protein interaction services.

Hybrigenics SA <i>Million EUR</i>	2011	2010	% change
Total operating revenues	6.6	4.6	+43%
Total operating costs	9.3	9.4	-1%
Operating loss	-2.7	-4.9	-45%
Net loss	-2.1	-4.6	-54%
Cash burned	-2.1	-3.6	-42%
Cash raised	2.7^a	2.4^b	+13%
Cash position at year end	2.7	2.4	+13%

^aincluding EUR 1.7 million drawings on an equity line with Yorkville GA, EUR 0.65 million zero interest loan from Oseo Innovation and EUR 0.3 million from a TEPA capital increase; ^bincluding EUR 1.6 million drawings on the Yorkville GA equity line and a EUR 0.8 million refundable subsidy from Oseo Innovation

Hybrigenics' total revenues increased by EUR 2 million in 2011 over 2010 (+43%), mainly thanks to an upfront payment related to the research collaboration with Servier on deubiquitinating enzymes as innovative drug discovery targets. Expenses have been contained to the same level as in 2010. As a result, operating and net losses were decreased by 45% and 54%, respectively.

From January to September 2011, EUR 1.7 million were drawn on the equity line with Yorkville GA (an amount similar to the EUR 1.6 million drawn on the same equity line in 2010). A EUR 0.3 million TEPA capital increase and a EUR 0.65 million zero interest loan from Oseo Innovation completed Hybrigenics' fund-raising for 2011. In addition, Hybrigenics received EUR 0.44 million as research tax credit. As a result, the cash position stood at EUR 2.7 million on December 31st, 2011, *i.e.* EUR 0.3 million more than on December 31st, 2010.

In 2011, Hybrigenics managed to design, get approved, finance and launch a clinical efficacy study of inecalcitol in moderate to severe psoriasis by oral administration. This double-blind trial vs. placebo has enrolled 60 patients in just 6 weeks before Christmas 2011 in the University Hospital of Nice, France. The last patient received his last treatment on April 6th, 2012, the follow-up period will end in May 2012 and the first results are expected one month later.

HYBRIGENICS

Press Release

By mid-2011, Hybrigenics, in collaboration with the Necker Institute in Paris, identified chronic lymphocytic leukemia, an orphan disease, as a new therapeutic opportunity for oral inecalcitol: this has resulted earlier this year in an additional clinical trial authorization granted by the French National Agency for Drug Safety and in a successful fund-raising of EUR 3.3 million to finance it. The first patient could be enrolled by mid-2012.

In 2011, intellectual property (IP) activity has also been fruitful with the final granting process of two European patents, one on the therapeutic use of inecalcitol at high doses and one on "14-epimerization", a crucial step in the chemical synthesis of inecalcitol. American and worldwide patenting procedures are on track, in the footsteps of the European examinations. Both patents strengthen and prolong inecalcitol's IP protection up to 2029 and 2030, respectively.

Hybrigenics Services SAS <i>Million EUR</i>	2011	2010	% change
Total operating revenues	4.23	3.74	+13%
<i>Sales</i>	3.74	3.34	+12%
<i>Other operating revenues</i>	0.49	0.40	+23%
Total operating costs	3.75	3.43	+9%
Operating result	0.54	0.31	+74%
Profitability (before tax)	12.8%	8.3%	

In 2011, Hybrigenics Services' total revenues grew by 13% to EUR 4.23 million from EUR 3.74 million in 2010. This activity generated a EUR 0.54 million operating profit, in strong progression (+74%) over EUR 0.31 million in 2010. Based on this 2011 operating result, Hybrigenics Services' profitability stands at 12.8% of revenues for its second year as an autonomous subsidiary, up from 8.3% in 2010.

"2011 has been the most successful operational year in Hybrigenics' history: the highest revenues, the lowest losses, an improved cash position, services activity with both revenue and profitability growing, first research collaboration agreement with upfront, success milestones and royalties, two new patents and two new therapeutic indications for inecalcitol,..." said Rémi Delansorne, Hybrigenics' CEO, who added: *"with the successful completion of a EUR 3.3 million capital increase in March 2012, Hybrigenics is in a good position to maximize the strategic value of inecalcitol."*

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

HYBRIGENICS

Press Release

Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr